This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pallier, C.
Right arrow Articles by Pawlotsky, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pallier, C.
Right arrow Articles by Pawlotsky, J.-M.

 Previous Article  |  Next Article 

Journal of Virology, January 2006, p. 643-653, Vol. 80, No. 2
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.2.643-653.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Dynamics of Hepatitis B Virus Resistance to Lamivudine

Coralie Pallier,1,2,{dagger} Laurent Castéra,2,3,{dagger} Alexandre Soulier,2 Christophe Hézode,4 Patrice Nordmann,1 Daniel Dhumeaux,2,4 and Jean-Michel Pawlotsky2*

Department of Bacteriology and Virology, Hôpital de Bicêtre, Université Paris XI, Le Kremlin-Bicêtre,1 Department of Virology, INSERM U635, Hôpital Henri Mondor, Université Paris XII, Créteil,2 Department of Hepatology and Gastroenterology, Hôpital Haut-Lévêque, Université de Bordeaux, Bordeaux,3 Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Université Paris XII, Créteil, France4

Received 1 April 2005/ Accepted 26 October 2005

Lamivudine was the first approved inhibitor of hepatitis B virus (HBV) reverse transcriptase (RT). Lamivudine resistance develops in 53% to 76% of patients after 3 years of treatment. We extensively characterized the dynamics of HBV quasispecies variant populations in four HBV-infected patients who developed lamivudine resistance. Virological breakthrough was preceded by 2 to 4 months by the emergence of quasispecies variants bearing amino acid substitutions at RT position 204, i.e., within the YMDD catalytic motif (rtM204V/I). Three patients had a gradual switch from a YMDD variant population at baseline to a 100% lamivudine-resistant variant population, whereas the remaining patient had a fluctuating pattern of resistance variant dynamics. Careful analysis of amino acid substitutions located outside domain C of HBV RT, including those known to partially restore replication capacities in vitro, showed that the in vivo replication of HBV variants is driven by multiple forces, including intrinsic replicative advantages conferred by mutations accumulating outside domain C and the changing environment in which these variants replicate. Our findings also suggest that individual treatment optimization will require sensitive methods capable of detecting the emergence of viral resistance before the relevant variants acquire optimal replicative capacities.

* Corresponding author. Mailing address: Department of Virology, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. Phone: 33-1-4981-2827. Fax: 33-1-4981-4831. E-mail: jean-michel.pawlotsky{at}hmn.aphp.fr.

{dagger} C.P. and L.C. contributed equally to this study.

Journal of Virology, January 2006, p. 643-653, Vol. 80, No. 2
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.2.643-653.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pawlotsky, J.-M. (2009). Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therapeutic Advances in Gastroenterology 2: 205-219 [Abstract]  
  • Solmone, M., Vincenti, D., Prosperi, M. C. F., Bruselles, A., Ippolito, G., Capobianchi, M. R. (2009). Use of Massively Parallel Ultradeep Pyrosequencing To Characterize the Genetic Diversity of Hepatitis B Virus in Drug-Resistant and Drug-Naive Patients and To Detect Minor Variants in Reverse Transcriptase and Hepatitis B S Antigen. J. Virol. 83: 1718-1726 [Abstract] [Full Text]  
  • Dusheiko, G, Antonakopoulos, N (2008). Current treatment of hepatitis B. Gut 57: 105-124 [Full Text]  
  • Libbrecht, E., Doutreloigne, J., Van De Velde, H., Yuen, M.-F., Lai, C.-L., Shapiro, F., Sablon, E. (2007). Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay. J. Clin. Microbiol. 45: 3935-3941 [Abstract] [Full Text]  
  • Heipertz, R. A. Jr., Miller, T. G., Kelley, C. M., Delaney, W. E. IV, Locarnini, S. A., Isom, H. C. (2007). In Vitro Study of the Effects of Precore and Lamivudine-Resistant Mutations on Hepatitis B Virus Replication. J. Virol. 81: 3068-3076 [Abstract] [Full Text]  
  • Tenney, D. J., Rose, R. E., Baldick, C. J., Levine, S. M., Pokornowski, K. A., Walsh, A. W., Fang, J., Yu, C.-F., Zhang, S., Mazzucco, C. E., Eggers, B., Hsu, M., Plym, M. J., Poundstone, P., Yang, J., Colonno, R. J. (2007). Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present. Antimicrob. Agents Chemother. 51: 902-911 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»